The versatile multi-functional substance NMN: its unique characteristics, metabolic properties, pharmacodynamic effects, clinical trials, and diverse applications

This wide-ranging review covers how NMN is made and metabolized, proposed biological mechanisms, animal studies, human trials, and possible applications. Animal and laboratory studies report many effects, but human findings are less consistent and generally come from small, short trials. The review highlights unresolved questions about dose, long-term safety, product purity, individual variation, and regulation.

The paper describes NMN as an NAD+ precursor with extensive mechanistic and preclinical research across metabolic, neurologic, cardiovascular, ocular, renal, reproductive, and other models. Human trials using roughly 100–1,250 mg/day for several weeks generally reported short-term tolerability and some biomarker or functional changes, but effects were less pronounced and less consistent than in animals. The authors note that clinical evidence remains limited and that standardized dosing, product quality, and regulatory approaches are lacking.

The review is broad and narrative, with no formal risk-of-bias assessment or meta-analysis. It combines cell, animal, and human evidence across highly varied conditions, doses, routes, formulations, and outcomes. Much of the positive evidence is preclinical. Human studies were generally small and short, with inconsistent findings. Long-term safety, optimal dosing, product purity, individual variation, and regulatory status remain uncertain.